Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $42,518 | $46,385 | $46,159 | $45,006 | $48,300 |
| Gross Profit | $30,745 | $36,445 | $36,022 | $34,313 | $34,332 |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$9,015 | $6,994 | $6,327 | $8,025 | -$8,948 |
Over the past five years, Bristol-Myers Squibb’s revenue and gross profit figures have shown overall stability with modest fluctuations, while net income has experienced notable volatility. Revenue increased from US$42.5 billion in 2020 to a peak of US$48.3 billion in 2024, although the trend was not strictly upward. Gross profit similarly rose from US$30.7 billion in 2020 to around US$36.4 billion in 2021 before slightly tapering to about US$34.3 billion in 2023 and 2024. It is important to note that operating income is consistently reported as zero, which might reflect adjustments or data aggregation issues in the reported income statement for these years. In contrast, net income exhibited significant swings over the period. The company recorded a substantial loss of US$9.0 billion in 2020, recovered to a profit of US$6.99 billion in 2021, maintained healthy profitability in 2022 (US$6.33 billion) and 2023 (US$8.03 billion), but then reversed sharply to a loss of US$8.95 billion in 2024 – a drastic year-over-year swing exceeding 20%. These reversals could be driven by extraordinary expenses, cost adjustments, or other one-time items that are reflected in net income. Taken together, while the steady revenue and gross profit levels suggest that the company remains competitive in the pharmaceutical industry, the volatile net income points to potential underlying operational or non-operational challenges. Overall, Bristol-Myers Squibb’s financial health appears robust in terms of revenue generation and gross profitability, but the significant fluctuations in net income warrant a closer review to ensure long-term sustainability and stability.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.